Slash the price of anti-HIV jab by three-quarters, says government:

The health department says ViiV Healthcare’s newly announced nonprofit price — between R540 and R570 a shot — for a two-monthly anti-HIV jab is more than four times what it can afford to pay.
ViiV confirmed the price to Bhekisisa in an email; it was also shared with activists and donors earlier this month. The amount has come down from a previous tag of R729 a jab, which wasn’t officially announced by ViiV, but was, for the past year, widely regarded as the agreed-upon price by influential scientists and policymakers.
The jab, made by the UK-based drug company, essentially wipes out someone’s chances of contracting HIV through sex, if taken every eight weeks. The medication, which is injected into the buttocks, contains an antiretroviral drug, cabotegravir, that is released over a two-month period, which is why it’s called CAB-LA (short for long-acting cabotegravir).
Antiretroviral drugs are the same medication that HIV-infected people take to keep the virus at bay, but in the case of CAB-LA, it’s used as pre-exposure prophylaxis, also known as PrEP. In other words, the medication protects an uninfected person from contracting the virus.
Just over 13% of the South African population has HIV, according to the Thembisa model, and an estimated 164 228 people were infected with the virus in 2022.
ViiV is selling CAB-LA, which was registered with South Africa’s medicines regulator in December 2022, at £24.70 (about R570) a shot in 2023 and £23.50 (about R540) in 2024 to 90 countries that the World Bank classifies as having low- and middle-income status. This group includes all sub-Saharan African states, as well as donors who will buy it on behalf of most African countries. The jabs won’t be sold individually, but only in packs of 25 vials.
In the United States, ViiV sells CAB-LA for $ 3 700 (about R70 000, depending on the exchange rate) a pop; some health insurance companies pay for it upon a doctor’s prescription. The nonprofit price is therefore about 127 times cheaper than what a US customer would pay, but it is still more than four times what the health department pays for a daily HIV prevention pill (R64.50 for a month’s supply per patient, according to the department). The pill also lowers someone’s chances of infection significantly — but only if it’s taken each day, with which some people struggle.
“For CAB-LA to be cost effective to the South African government, the price would need to be within a reasonable range of oral PrEP [the daily pill], which is R129 for a two-month supply. We can’t afford to pay double or thrice the price, especially not within the context of the budget cuts our department has faced,” says the national health department’s chief director of procurement, Khadija Jamaloodien.
Finance Minister Enoch Godwongana announced a R1 billion cut from the health department’s HIV treatment budget in his medium-term budget earlier this month.
“What’s more,” says Jamaloodien, “is that ViiV’s non-profit price doesn’t include distribution costs, so it will be even higher than the currently quoted R540—R570 per vial.
“We’ve asked ViiV for a quote in South African rands that includes transport and logistics, as we do with all our other tenders. We’re still waiting to hear back.”
Malawi, Zambia and Zimbabwe’s shipments on the way
One way of getting around CAB-LA’s high price is to allow donors such as the US government’s President’s Emergency Plan for Aids Relief, Pepfar, to pay for it. Pepfar has paid the most of any government donor for antiretroviral treatment in Africa and also funds oral PrEP in several African countries.
ViiV has already shipped Pepfar-sponsored supplies to Malawi, Zambia and Zimbabwe, which will arrive in late November, according to Mitchell Warren of the Coalition to Accelerate Access to Long-Acting PrEP. ViiV has confirmed the shipment to Bhekisisa, but not the donor or countries.
Warren, however, says the US government has confirmed that the stock was bought by Pepfar. The coalition is a group convened by Pepfar, the Global Fund, UNAids, Unitaid and the World Health Organisation; Avac, the New York-based advocacy group which Warren heads up, is the secretariat.
Between 2023 and 2025, Malawi is expected to receive 10 000 jabs, Zimbabwe between 10 000 and 12 000, and Zambia between 8 000 and 10 000. The stock will be used by government health programmes and not for research.
Warren, and also several South African HIV researchers, says Pepfar has told them that South Africa is on the list for donations for programmatic use in early 2024. But Pepfar told Bhekisisa it’s “not able to comment on this issue at this stage because we are still in a deliberative stage with the national health department and other stakeholders”.
The health department, however, says it is yet to decide if it will accept CAB-LA donations.
Jamaloodien explains: “It’s certainly not something we will outright refuse, but we also need to look at sustainability. South Africa, for instance, pays for all its antiretroviral drugs for HIV treatment itself, and we still have to consider what route we will follow with CAB-LA.”
Will people use the jab?
In early 2024, South Africa will receive ViiV-sponsored CAB-LA shipments that will be used in implementation studies (in other words, for research purposes). According to health department data, seven such trials will start as soon as the stock arrives and has been approved for distribution by the South African Health Products Regulatory Authority.
The studies will be carried out by the Wits Reproductive Health Research Institute and Ezintsha at Wits University, the Africa Health Research Institute at the University of KwaZulu-Natal, the Desmond Tutu Health Foundation at the University of Cape Town, the South African Medical Research Council and the Human Sciences Research Council.
Implementation studies look at how well people adhere to treatment in “real life”, the best ways to get the medicine to them and how to create demand for a product (as opposed to whether the drug works, because implementation trials are done only after efficacy data has become available).
“We’ll count how many people come for CAB-LA, check which groups are using it, who struggles, and how people adhere to it within the context of all the ups and downs of a ‘real life’ health system,” explains Linda-Gail Bekker, who will head up the Desmond Tutu Health Foundation’s implementation study.
“It’s pretty much the same as when people go to a public health facility to fetch medicines, with the difference that we carefully monitor the use of the medicine so that it can inform mass roll-out.”
Warren says ViiV has told the Coalition it will be able to make 995 000 CAB-LA jabs for low- and middle-income countries between 2023 and 2025 at its nonprofit price (up from a previous commitment of between 360 000 and 590 000 vials).
“It’s still short of what we think the market might be, but the reality is that we simply don’t yet know what the market size will be,” Warren explains. “That’s why we need all the implementation studies — to show us if the novelty experience and good uptake during efficacy trials translate into ‘real life’ uptake.”
Lesson from America
In the United States, where CAB-LA became available in late 2021, uptake has been slow, a small study presented at Infectious Diseases Week (an annual meeting of infectious diseases experts in the US) shows — mainly because of the high cost and the complicated admin of health insurance companies.
Only slightly more than half (52.9%) of HIV-negative study participants who got a prescription for CAB-LA followed through to get their first injection.
“An important lesson to learn from this is that you need to make it easy for people to get preventive medication if you’d like them to use it,” says Bekker. “We may need to take CAB-LA into communities with mobile clinics or create separate, fast lines at clinics.”
CAB-LA jabs need to be injected deep into someone’s muscles and so have to be given by a health worker. Couriering shots to users is therefore not feasible — unlike for the daily pill, says Bekker.
Over a million people in South Africa have used the pill, which was introduced in 2016.
“We need to think about PrEP like we think about fast food delivery,” says Bekker. “You’ve got drive-throughs, at-home deliveries or pick-up points. So there’s a choice in how you’d like it to get your fast food. The more delivery options, the higher the chance that you’d order it.”
Since August, following a North Gauteng high court ruling, HIV prevention pills can be handed out by trained pharmacists, so users no longer have to go to a doctor for a prescription.
Bekker concludes: “This makes enormous sense, as we’d want a variety of pick-up points to make access as easy as possible.”
Can South Africa afford to go without CAB-LA?
In March, ViiV awarded licences to three Indian drugmakers to produce cheaper, generic versions of CAB-LA in collaboration with the Medicines Patent Pool, a United Nations-backed organisation that helps poorer countries to get access to medicines. One of the companies, Cipla, has a plant in Durban, where they’re planning to manufacture the jab.
But for this to happen, Cipla first needs to get get the technology in place (that process has started), build facilities and then, once they’ve produced the medicine, run trials that will prove their product works in the same way as the branded drug (this is known as bioequivalence trials).
Generic products will therefore become available in 2027, at the earliest, says Warren, which means until then, we need the price of the branded drug to be as low as possible.
“ViiV has indicated that as volumes go up, and they get orders from large buyers like Pepfar, the Global Fund and governments like South Africa, the [nonprofit] price could drop considerably. We believe within the next couple of years, the branded product could cost closer to $ 100 (about R1 830) or $ 120 (around R2 200) for a year’s injections [as opposed to the current $ 175 or R3 200—R3 400]”, Warren says.
CAB-LA is considerably more complex to make than oral PrEP, and the health department is able to get the pill at a low price because its ingredients (the antiretroviral drugs tenofovir and emtricitabine) are also widely used for HIV treatment in South Africa, so our tender allows for exceptionally large orders, which brings down the price.
Bekker, however, points out that CAB-LA’s affordability has two sides.
“We also have to say it’s very expensive for young women and men to become infected with HIV because we need to provide them with lifelong antiretrovirals, and there’s a risk that they can transmit the virus to others, and in the case of women, also to their babies.
“We need to ask what is the price tag for saving someone from an infection and therefore giving them a better handle on a healthy life.”

This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.
The post Slash the price of anti-HIV jab by three-quarters, says government appeared first on The Mail & Guardian.
Basketball nirvana comes at a cost:

The 2023-24 NBA season, which started less than a month ago, came with a newly refurbished League Pass app, as is customary. Every year the league seeks to improve on its product and give fans more basketball.
This year’s marketing campaigns have given us the taglines “So Much Game” and “Everyone’s NBA App”. And their output confirms this. There is indeed a lot of game and they really are going for it in trying to appeal to the masses as well as the sycophants.
This iteration of the League Pass app is jam-packed with information and designed to cover all bases. Pregame coverage, postgame coverage, team content, player content, breaking news, various analysis content, newsletters even, injury reports, referee information, statistics galore and around-the-clock NBA TV coverage to name a breathless few. It goes without saying that the league’s inaugural in-season tournament — think FA Cup loosely in football terms — is a prominent feature, too.
(Personally I’d still like to see an expanded game archive — it only goes back to the 2012-13 season — and some WNBA synching, but I digress into nerdy basketball territory.)
They’re leaving no stone unturned in terms of sheepdogging fans into one single product. The clearest evidence of this is the social media app type-interface they have gone for. If you’re an Instagrammer, TikToker, X-er (?) or whatever else, navigating the app is a breeze. Like those apps, there’s a lot less clicking and a lot more swiping — think Instagram stories except for your favourite player, team or league-wide highlights.
Further attempting to funnel “casual” fans from the other apps who might be interested in fringe basketball aspects like sneaker culture, they’ve collated them on this app. Wondering what Jayson Tatum or Russell Westbrook wore to last night’s game? Look no further, they’ve got it. Photos of the night? Ready. Only interested in the coolest dunks? There’s a tab for that. It really is NBA Disneyworld. That is, of course, unless you’re a no-frills fan who is simply there to watch actual games. Then I’d suggest you stick to the “Games” tab and swipe no further, lest you experience sensory overload or device overstimulation.
Speaking of which (and this is the biggest whet for someone like myself), you can now watch not one, not two, not three but four — yes — four different games at one time. I’m talking real basketball sicko mode. No more will you have to flip back and forth between enticing games scheduled in the same slot. You can now keep up with multiple live games on one screen if your attention span will allow it.
As always, it all comes down to price point and how much of a fanatic you are. A standard League Pass will cost South Africans R840 ($ 46) and Premium R1 130 ($ 62) for the entire season/yearly. There are monthly options, too, if you’re more of a playoffs-only or here-and-there fan, or if you simply can’t afford the entire bouquet.
On this continent, these rates still price out the masses — and the Democratic Republic of the Congo, Somalia, Sudan and Zimbabwe cannot access the app. But for the privileged minority who are NBA-obsessed, it’s a no-brainer in terms of quality and convenience.
The post Basketball nirvana comes at a cost appeared first on The Mail & Guardian.
Increasing xenophobia highlights the need for political change:

As the crisis deepens in South Africa we are all, including the middle classes, being squeezed to breaking point. The poor are in desperate circumstances suffering endemic unemployment and hunger. As the economy worsens the middle classes find themselves deeper and deeper in debt, and often struggling to keep their homes and to keep their children in decent schools.
We all suffer from Eskom’s failures, decaying infrastructure and the general sense of hopelessness brought about by the gross corruption of the state and Cyril Ramaphosa’s failure as a president. And although it’s certainly worse for the poor, the middle classes also live at constant risk of increasingly brazen and violent crime.
The new trend of kidnappings, often by people in police uniforms, to get access to people’s banking apps is terrifying. Nobody trusts the police; for many people they are just another gang.
South Africans are desperate and frightened for good reason. We all know that if we can’t find a way to change course the future will be hellish. But we need to be clear that we are in this crisis because the ANC has collapsed into a violent and corrupt organisation controlled by avaricious people with no concern for society. Of course, the colonial and apartheid past laid the basis for the crisis and white capital continues to exploit. But we elected the ANC to deal with all this. Instead it has become a predatory force devouring our hopes at every turn.
There is no party on the ballot for next year’s election that has any chance of channelling our fears into a viable alternative to the ANC. Parties such as the Economic Freedom Fighters and the Patriotic Alliance are likely to be as bad or worse than the ANC in power. The Democratic Alliance remains in the hands of a rightwing white cabal. The opinion polls do show that the ANC will be severely punished in the coming elections. But punishing a ruling party is not the same as building an alternative.
We need a credible vision for the future, but that vision has not emerged from electoral politics, nor from civil society. We do have a strong union in the National Union of Metalworkers of South Africa (Numsa), the biggest in Africa, which is effective at dealing with workplace issues and often runs strikes. But, unlike in the 1980s, the union movement is not able to give leadership to wider society. It defends its members well, but in a time of mass unemployment and political crisis we need much more than that.
Abahlali baseMjondolo is the largest movement of the urban poor anywhere in the world and is widely respected for its ethical leadership and democratic practices. Its last membership audit showed more than 120 000 members and this past weekend alone it launched six new branches. But the movement has never entered electoral politics; it doesn’t have a coherent strategy for this. Calling on its members to vote against the ANC cannot generate a coherent alternative to the ANC.
It was hugely heartening to see the scale of the protest in Cape Town for Palestine this past weekend. We were all reminded of the best of ourselves and that some of the legacy of the mass organisation of the 1980s remains. But we don’t see similar kinds of protests emerging from civil society to demand action against crime, unemployment and corruption. No leadership has emerged to organise and mobilise despite the scale and severity of the crisis.
Things cannot continue as they are. We all know this. And for as long as we fail to generate a credible electoral alternative or to generate a credible civil society response to the crisis there is a danger that desperate people will scapegoat others for the crisis. In South Africa we all know how this plays out. It is migrants who will be blamed.
In recent weeks the xenophobic discourse from the ANC has worsened and there has been an uptick in reports of xenophobic violence. Some of the media are, as usual, being irresponsible and repeating xenophobic ideas. There is now a risk of a full-blown social panic emerging around the idea that migrant-owned spaza shops are selling poisonous food to children. When the media and politicians treat this as credible, and when the police raid migrant-owned shops rather than shops in general, that risk is escalated.
Xenophobia, often mixed with Islamophobia in India, the United States and Europe, is central to the politics of the new right. They ignore the damage that out of control capitalism has done to people and the institutions on which they depend and instead tell people that their lives are getting worse because of migration. This is patently nonsense but when people believe it they turn on each other and don’t confront their rulers. Cultivating xenophobia has become a very successful strategy for rightwing populists around the world.
There is a huge risk that as the ANC realises that it could well lose power in the next election it will seek a quick fix rather than starting to fix Eskom and the police, deal with poverty and get the economy going. That quick fix would almost certainly take the form of actively cultivating xenophobia and scapegoating migrants for the ANC’s own failures.
This is an alarming prospect. For one thing, if it is effective the ANC will continue to damage the country while its people attack migrants instead of opposing their new oppressors. For another, the risks of violence against migrants by both the police and street mobs will go through the roof. Any decent person must shudder at this thought.
In this time of crisis it is urgent that we build an alternative to the ANC, but we lack leadership.
This cannot be overstated. But it is also vital that we build a united front to oppose xenophobia and all other attempts to scapegoat vulnerable groups for the state’s failure.
Civil society cannot take on the project of building a political party in a unified way. But it can take on the project of building a united front against xenophobia. We need a crisis civil society meeting with all the most important players in one room. This must include the organisations such as labour federation Cosatu, Numsa and Abahlali baseMjondolo, the progressive religious organisations and the progressive NGOs (who need to set aside their hugely damaging sectarianism). That meeting needs to come out with a declaration of opposition to xenophobia and solidarity with migrants and a strategy to organise in support of the declaration.
We need, in the words of Martin Luther King, to act with “the fierce urgency of now”.
Dr Buccus is senior research associate at the Auwal Socio-economic Research Institute and post-doctoral fellow at the Durban University of Technology
The post Increasing xenophobia highlights the need for political change appeared first on The Mail & Guardian.
Submit and get free exposure here: Showcase Your Business | Advertise Your Special Offers.

